CMS launched a voluntary Medicare payment model designed to broaden coverage of GLP‑1 therapies for weight loss and diabetes. The agency framed the pilot as a mechanism to lower beneficiary out-of-pocket costs and negotiate programmatic payment structures; the proposal builds on prior policy moves aimed at curbing drug prices. GLP‑1 receptor agonists and related incretin drugs are a class of diabetes and obesity medicines widely used for metabolic indications. Policymakers and payers will watch enrollment terms and reimbursement mechanics closely, since changes could shift market access, formulary strategies and manufacturer pricing for prominently used biologics.